Açai weight loss sites operater to pay $2 million to settle FTC case

Related tags Fraud

A defendant that hawked deceptive açai weight loss products via fake news websites has agreed to pay more than $2 million to settle a case brought by the Federal Trade Commission.

Circa Direct LLC and Andrew Davidson were charged with using phony websites that made it appear as if news programs had reviewed the effectiveness of the acai products.  The sites constituted deceptive advertising, the FTC charged. As an example, FTC cited a piece in which a “reporter” claimed to have lost 25 pounds using the products.

The total settlement judgment amounts to $11.5 million, but will be suspended after FTC received the $2 million in proceeds from the defendant’s personal and corporate bank accounts, other financial assets and the sale of a house and a car.

Under the settlement, Circa Direct and Davidson are barred from passing off ads as fake news websites and must disclose financial connections they may have with merchants.  They are also barred from making deceptive and misleading claims about health-related products.

Related news

Show more

Related products

show more

MOROSIL:INGREDIENT OF THE YEAR

MOROSIL:INGREDIENT OF THE YEAR

Content provided by BIONAP BIOACTIVE NATURAL PRODUCTS | 07-Mar-2024 | Product Brochure

MOROSIL™ has won as Ingredient of the Year in the category Weight Management at 2023 Nutraingredient USA. MOROSIL ™ is a standardized extract derived from...

In Weight Management Go Beyond with Slendacor®

In Weight Management Go Beyond with Slendacor®

Content provided by PLT Health Solutions | 22-Feb-2024 | White Paper

Slendacor® is a synergistic, patented formulation of three standardized herbal extracts: turmeric (Curcuma longa), moringa (Moringa oleifera) and curry...

Polyphenol extracts as weight management catalysts

Polyphenol extracts as weight management catalysts

Content provided by DolCas Biotech, LLC. | 18-Jan-2024 | White Paper

Viable natural product options for "healthy weight management" in the age of Ozempic and other GLP-1 inhibitors will require targeted innovations...

Related suppliers

Follow us

Products

View more

Webinars